BiotechTube
GT Medical Technologies

GT Medical Technologies

United States
gtmedtech.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $50M

Overview

GT Medical Technologies is a commercial-stage private company pioneering a novel approach to intraoperative radiation therapy for brain tumors. Its core innovation, GammaTile, is a tile-shaped, bioresorbable collagen carrier pre-loaded with Cesium-131 radiation seeds, which surgeons implant at the tumor resection site. This technology eliminates the typical post-surgical delay for external beam radiation, provides highly conformal dose delivery to reduce recurrence, and aims to spare healthy brain tissue. The company is currently focused on commercializing GammaTile for recurrent and newly diagnosed malignant brain tumors, including glioblastoma, brain metastases, and recurrent meningiomas.

OncologyNeurosurgeryRadiation Oncology

Technology Platform

Bioresorbable collagen tile matrix pre-loaded with Cesium-131 radiation seeds for surgically targeted, immediate, and conformal brachytherapy.

Funding History

3
Total raised:$50M
Debt$15M
Series B$25M
Series A$10M

Opportunities

Large addressable market in glioblastoma and brain metastases where current standard radiation therapy has significant delays and side effects.
The platform's potential for expansion into other resectable solid tumors (e.g., spinal, head & neck) presents a long-term growth avenue.
The value proposition of condensed treatment and reduced side effects aligns strongly with healthcare trends towards value-based and patient-centric care.

Risk Factors

Commercial adoption risk in a conservative surgical specialty with established workflows.
Competition from advanced external beam radiation (SRS/SRT) and other intraoperative devices.
Ongoing challenges with reimbursement and pricing from insurers.
Long-term safety data is still maturing, and the complex regulatory environment for radioactive devices adds operational cost and complexity.

Competitive Landscape

GammaTile competes primarily with external beam radiation therapy (EBRT) and stereotactic radiosurgery (SRS/SRS) systems (e.g., Varian, Elekta, Accuray). It also faces competition from other intraoperative radiation therapy (IORT) platforms like the Zeiss INTRABEAM (low-energy X-rays) and intraoperative high-dose-rate (HDR) brachytherapy. Its key differentiators are the immediate treatment at surgery, the conformal dose from the tile spacer, and the use of bioresorbable materials.

More companies in Radiopharmaceuticals →More companies in United States →